Skip to content

Nuvalent, Inc. NUVL Total Liabilities

Total Liabilities at other companies

Pfizer logo
PfizerPFE
$3.41B-97.1%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$1.52B+69.5%
Summit Therapeutics logo
Summit TherapeuticsSMMT
$101.92M+158%
Exelixis logo
ExelixisEXEL
$657.85M-6.9%
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
$753.82M+162%
Incyte logo
IncyteINCY
$1.72B-17.6%

Other financials

Income statement

See full
Operating income-$119.4M-25.9%
Net income-$109.3M-29.2%
EPS (diluted)-$1.39-17.8%

Balance sheet

See full
Cash & equivalents$159.7M+32.2%
Total equity$1.2B+16.2%
Total assets$1.3B+20.4%

Cash flow

See full
Operating cash flow-$92.4M-68.5%

Valuation

See full
Market cap$9.77B+58.6%

Returns & leverage

See full
Return on equity-41.2%+7.5pp
Current ratio16.1×+1.7×

Where this comes from

Reported directly by Nuvalent, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Liabilities.

The official record: Nuvalent, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvalent, Inc.'s total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvalent, Inc.'s total liabilities?
Nuvalent, Inc. (NUVL) reported total liabilities of $156.78M in Q1 2026.
How has Nuvalent, Inc.'s total liabilities changed year-over-year?
Nuvalent, Inc.'s total liabilities increased by 65.5% year-over-year, from $94.75M to $156.78M.
What is the long-term trend for Nuvalent, Inc.'s total liabilities?
Over 5 years (2020 to 2025), Nuvalent, Inc.'s total liabilities has grown at a 90.1% compound annual growth rate (CAGR), from $6.62M to $164.37M.
What does total liabilities mean?
The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.